Everolimus
A mammalian target of rapamycin inhibitor.
General information
Everolimus is a lactone derivative used as an immunosuppressant. It inhibits mammalian target of rapamycin (mTOR). Everolimus was suggested to inhibit SARS-CoV-2 infection via mTOR inhibition (although by an unknown mechanism) (Mullen et al., 2021; NCIt).
Everolimus on DrugBank
Everolimus on PubChem
Everolimus on Wikipedia
Marketed as
AFINITOR; AFINITOR DISPERZ; CERTICAN; EVEROLIMUS; VOTUBIA; ZORTRESS
C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OCCO)C)/C)O)OC)C)C)/C)OC
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
The Host Cell ViroCheckpoint: Identification and Pharmacologic Targeting of Novel Mechanistic Determinants of Coronavirus-Mediated Hijacked Cell States
Preprint |
in silico | one of the top drugs and compounds identified by ViroTreat |
May/17/2020 | |
|
Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2
Preprint |
human renal cortical epithelial cells | Apr/23/2020 | ||
|
SARS-CoV-2 infection rewires host cell metabolism and is potentially susceptible to mTORC1 inhibition
Small molecule In vitro |
Vero cells; human lung air-liquid interface cultures; SARS-CoV-2 isolate USA-WA1/2020 | 12.12 | Inhibited SARS-CoV-2 replication in Vero cells, possibly through mTORC1 inhibition. |
Mar/25/2021 |
